Stephen Yoo Sells 32,658 Shares of REGENXBIO Inc. (RGNX) Stock
REGENXBIO Inc. (NASDAQ:RGNX) insider Stephen Yoo sold 32,658 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $25.00, for a total transaction of $816,450.00. Following the sale, the insider now owns 31,803 shares in the company, valued at $795,075. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
REGENXBIO Inc. (NASDAQ:RGNX) traded up 1.43% during midday trading on Thursday, hitting $24.80. 249,197 shares of the stock were exchanged. The company’s 50 day moving average is $20.30 and its 200 day moving average is $19.76. The company’s market capitalization is $766.17 million. REGENXBIO Inc. has a 1-year low of $12.81 and a 1-year high of $25.00.
REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. The company had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. Analysts predict that REGENXBIO Inc. will post ($2.87) earnings per share for the current fiscal year.
RGNX has been the topic of a number of analyst reports. Chardan Capital increased their price objective on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Saturday, August 12th. BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Finally, Evercore ISI initiated coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. REGENXBIO has an average rating of “Buy” and an average price target of $37.00.
Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc increased its position in shares of REGENXBIO by 41.4% in the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares during the last quarter. Oxford Asset Management bought a new position in shares of REGENXBIO in the first quarter worth approximately $206,000. American International Group Inc. increased its position in shares of REGENXBIO by 7.1% in the first quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 822 shares during the last quarter. Voya Investment Management LLC bought a new position in shares of REGENXBIO in the second quarter worth approximately $249,000. Finally, Asymmetry Capital Management L.P. increased its position in shares of REGENXBIO by 12.2% in the second quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 1,508 shares during the last quarter. Institutional investors own 73.23% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.